Many researchers have identified CDCA8 as a novel oncogene, which predicts a poor prognosis in HCC as well as promotes tumor proliferation via MEK/ERK, AKT/β-Catenin, and CDK1/cyclin B1 signaling (Jeon et al., 2021; Cui and Jiang, 2023). This evidence concerns the gene MAP2K7 and hepatocellular carcinoma.